Loading
Loading
Research Overview
Alpha-MSH tripeptide fragment (Lys-Pro-Val); binds melanocortin MC1 and MC3 receptors to suppress NF-κB activation and reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-8), with particular focus on mucosal and intestinal inflammation models.
KPV (Lysine–Proline–Valine) is a short-chain peptide fragment derived from the larger melanocortin peptide Alpha-Melanocyte-Stimulating Hormone (α-MSH). In preclinical research, KPV has been investigated for its potential involvement in inflammatory signaling and immune-related processes. Due to its compact structure—composed of just three amino acids—it has attracted attention in experimental models exploring peptide-mediated regulatory mechanisms, particularly those associated with localized tissue responses.
Across laboratory and animal-based studies, KPV has been examined for its potential interactions with pathways linked to inflammation and immune modulation. Research has explored how this peptide may influence cytokine activity, cellular signaling cascades, and receptor-mediated responses involved in maintaining physiological balance. Some investigations suggest that KPV may interact with pathways associated with nuclear factor signaling and inflammatory mediators, making it a subject of interest in controlled experimental environments focused on immune response dynamics.
In addition to inflammation-related research, KPV has been evaluated in experimental models studying barrier function and tissue integrity, particularly within epithelial systems such as the gastrointestinal tract and skin. These studies often assess how KPV may influence cellular repair mechanisms, oxidative stress responses, and localized signaling processes under induced conditions.
To support consistency in experimental settings, KPV is synthesized and utilized in stabilized forms for laboratory research. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, kpv peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
KPV Peptide research is most relevant to protocols examining:
Intestinal and mucosal inflammation research
NF-κB pathway and melanocortin receptor immunology studies
TNF-α and IL-6 suppression investigations
Researchers studying gut-targeted anti-inflammatory peptides
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Alpha-MSH tripeptide fragment (Lys-Pro-Val); binds melanocortin MC1 and MC3 receptors to suppress NF-κB activation and reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-8), with particular focus on mucosal and intestinal inflammation models.
| Parameter | Value |
|---|---|
| Dose range | 100–500 mcg/day |
| Schedule | Daily |
| Route | Subcutaneous, Oral (gut-targeted) |
| Half-life | ~Hours |
limited human data
Community & Anecdotal Signal
Community signal is emerging rather than established, KPV is less widely known than catalog peers and the anecdotal pool is accordingly thin. Gut health applications dominate what discussion exists, particularly among users with IBD-adjacent symptoms or leaky gut concerns. Topical use for inflammatory skin conditions generates occasional reports on dermatology forums. The community interested in KPV tends to be more research-aware than average given the compound's lower mainstream profile. Most reports acknowledge the in vitro and animal evidence as the basis for use, with genuine uncertainty
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
